...
首页> 外文期刊>Pediatric transplantation. >Low toxicity of a conditioning with 8-Gy total body irradiation, fludarabine and cyclophosphamide as preparative regimen for allogeneic hematopoietic stem cell transplantation in pediatric hematological malignancies.
【24h】

Low toxicity of a conditioning with 8-Gy total body irradiation, fludarabine and cyclophosphamide as preparative regimen for allogeneic hematopoietic stem cell transplantation in pediatric hematological malignancies.

机译:以8-Gy全身照射,氟达拉滨和环磷酰胺为小儿血液系统恶性肿瘤的异基因造血干细胞移植的制备方案的低毒。

获取原文
获取原文并翻译 | 示例

摘要

We here report the efficacy and toxicity of a conditioning regimen with fractionated 8-Gy TBI, fludarabine, and cyclophosphamide in allogeneic HSCT for pediatric hematological malignancies. Among 22 children who received related or unrelated HSCT, nine were transplanted with refractory disease and/or from HLA two or more loci-mismatched family donors. None of the patients developed graft failure. The Seattle grading system revealed that 18 patients had no RRT, and the remaining patients had grade I gastrointestinal toxicity alone. The estimated overall survival and leukemia-free survival at two yr were 57.1% and 48.0%, respectively, in 10 patients with acute lymphoblastic leukemia; 91.7% and 71.3%, respectively, in 12 patients with myeloid leukemia. The incidence of TRM was 4.8% at two yr. The rates of RRT above grade II and TRM in an 8-Gy TBI-containing regimen were significantly lower than the data of historical control patients who underwent 12-Gy TBI and cyclophosphamide with or without etoposide. The intermediate-dose TBI-based conditioning regimen may confer successful engraftment combined with minimized RRT, although its efficacy should be further evaluated.
机译:我们在这里报告了同种异体HSCT中分级8-Gy TBI,氟达拉滨和环磷酰胺调理方案对儿童血液系统恶性肿瘤的疗效和毒性。在接受相关或不相关HSCT的22名儿童中,有9名患难治性疾病和/或从HLA移植了两个或多个基因座不匹配的家庭供体。没有患者发生移植失败。西雅图分级系统显示18例患者无RRT,其余患者仅具有I级胃肠道毒性。 10名急性淋巴细胞白血病患者的两年总生存率和无白血病生存率估计分别为57.1%和48.0%。 12例髓样白血病患者分别为91.7%和71.3%。两年中TRM的发生率为4.8%。在含8 Gy TBI的方案中,RRT高于II级和TRM的比率显着低于接受12 Gy TBI和环磷酰胺加或不加依托泊苷的历史对照患者的数据。尽管应进一步评估其疗效,但基于中剂量TBI的调理方案可能会成功植入并结合最小的RRT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号